HSP90 Inhibitors as Therapy for Multiple Myeloma
| Autor: | Gabriela Chiosis, Saad Z. Usmani |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
Drug Evaluation Preclinical Antineoplastic Agents Biology Mitochondrion Clinical Trials Phase II as Topic Heat shock protein medicine Animals Humans HSP90 Heat-Shock Proteins Multiple myeloma Clinical Trials Phase I as Topic Endoplasmic reticulum Cell Cycle Hematology medicine.disease Hsp90 Cell biology Oncology Cytoplasm Unfolded protein response biology.protein Cancer research Signal transduction Multiple Myeloma Signal Transduction |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 11:S77-S81 |
| ISSN: | 2152-2650 |
| Popis: | The heat shock protein 90 (HSP90) family of proteins are ubiquitous molecular chaperones that are intricately involved in folding, activation, maturation, and assembly of many proteins that include essential mediators of signal transduction and cell cycle progression. They are abundant in eukaryotic cells and localized to the cytoplasm and mitochondria as well as the endoplasmic reticulum under normal conditions, making up 1% to 2% of all cellular proteins. HSP90 proteins have increased expression in a number of malignancies, including multiple myeloma. HSP90 inhibition can influence multiple oncogenic pathways and proteins involved in myeloma, therefore making it an attractive target for drug development in this disease. This article serves as an overview of the pre-clinical data and clinical trial data on HSP90 inhibitors in multiple myeloma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect